# Simple measures can improve care in our hospitals - an audit of venous thromboembolism practice

## Thomas Lofaro, Stephanie Azzopardi, Sarah Busuttil, John Cordina

### Abstract

Venous thromboembolism (VTE) is a serious but preventable complication of hospitalisation. Doctors still sometimes fail to adhere to them, thus putting patients at risk and incurring considerable expense for the national health service. We chose to audit the practice of doctors in our geriatric facility, and assessed the effect of a memoire to increase compliance. We also explore how our hospitals can learn from the experience of other centres, where the risk of litigation has brought this condition to the forefront. Compliance improved from 30.7% to 63.3%, which was statistically significant. We would suggest that a centralised and organised approach could produce even greater levels of compliance.

#### Keywords

Deep vein thrombosis, pulmonary embolism, venous thromboembolism, prophylaxis, geriatric medicine

Thomas Lofaro MRCP (UK) *
c/o 21, Fr. Guze` Delia Street,
Hal Balzan. BZN 1713. or
Flat 53, Boland House,
St. Thomas' St,
London. SE1 9RT. UK.
thomas.lofaro@nhs.net
Stephanie Azzopardi
Stephanie Azzopardi Sarah Busuttil
Stephanie Azzopardi Sarah Busuttil John Cordina FRCP (Edin)

Hospitalisation is known to be a particularly important risk factor for venous thromboembolism (VTE),<sup>1,2,3,4</sup> and good clinical practice requires that all inpatients are risk-assessed repeatedly for predisposition to this disease.<sup>5</sup> Medical patients are less likely to be adequately risk-assessed than other patients, despite accounting for the majority of reported cases of VTE.<sup>1,3,6</sup> We wanted to investigate the level of compliance with guidelines in our geriatric facility, and whether we could improve it with simple measures to increase awareness.

### Method

We used the guidelines by the Scottish Intercollegiate Network (SIGN) as our benchmark,<sup>5,9</sup> and data was collected by retrospective review of patient-notes. We included the first 40 patients discharged from hospital or deceased, starting from an arbitrary date. This value was chosen because it corresponded to 20% of the inpatient capacity at the time. Patients were only excluded if they were on anticoagulation or if their notes were irretrievable. Risks of thrombosis were considered high if patients had more than two risk factors for VTE, or if they were recovering from hip, knee or abdomino-pelvic surgery. We noted the indications for prophylaxis, documentation of risk-assessment, preventative measures used and any contraindications. For each case, we noted whether management followed guidelines as suggested by SIGN. Since most patients are transferred from acute care, some were already on prophylaxis at the time of admission to our facility. We reported outcome as the proportion of patients adequately risk-assessed and treated.

We designed a simple memoire on an A4-sheet to remind different members of the multidisciplinary team of the importance of risk-assessment (see figure 1). It included a list of the commoner risk factors, and was circulated to all wards and attached to patients' treatment charts. We then repeated our audit a few months later and compared the outcomes.

<ul> <li>Risk Factors for Venous thromboembolism:         <ol> <li>Active malgnancy within 6 months</li> <li>Obesity</li> <li>Obesity</li> <li>Previous venous thromboembolism</li> <li>Previous venous thromboembolism</li> <li>Revious venous thromboembolism</li> <li>Revious venous thromboembolism</li> <li>Restore venus</li> <li>Varicose veins</li> <li>Sepsis</li> <li>Myeloproliferative disease, Behçer's disease, Faroxysmal nocturnal haemoglobinutia, Heparin-induced thrombocytopoenia, Inflammatory bowel disease, Central venous catheterization</li> <li>Preferred in most patients, unless contraindicated.</li> <li><sup>10</sup> Preferred in most patients, unless contraindicated.</li> <li><sup>10</sup> Should not be used no mous catheterization</li> <li><sup>10</sup> Preferred in most patients, unless contraindicated.</li> <li><sup>10</sup> Preferred in most patients, and particularly in orthopaedic patients.</li> <li><sup>10</sup> One should consider contraindicated.</li> <li><sup>10</sup> May be used in combination with medical therapy in high risk patients, and particularly in orthopaedic patients.</li> <li><sup>10</sup> The dose of enoxaparin may need to be decreased in patients with a creatinical creatinical creations before implementing mechanical methods.</li> </ol></li></ul>	ORTHOPAEDIC SURGERY: Patients undergoing THR/TKR should receive pharmacological prophylaxis in combination with physical methods. Treatment should be continued for 14 days after TKR, Treatment should be continued for 28-35 days after THR/hip fracture surgery and in all those with additional risk factors.	GYNAECOLOGICAL AND GENERAL SURGERY: Prophylaxis should be considered for all patients undergoing major surgery, and for those having minor procedures if they have additional risk factors for VTE. Mechanical methods, UFH or LMWH are all effective. Combination of mechanical and pharmacological methods should be used after abdominal surgery. Prophylaxis is indicated until mobility is regained, and for a further 2-4 weeks in high risk individuals.	t heparin, TXR: total knee replacement, THR: total hip replacement re of the elderly undergoing physical rehabilitation. Newer medical methods of prophylaxis (e.g. dividual cases
Age > 60 Actrely unwell OR Untriple Risk Factors <sup>1</sup>	Pharmacological <sup>4</sup>	UEH 5000 SC     Graduated     Adequate hydration       bd/rts OR 7500U     compression     Early mobilisation       sc bd     stockings     Physiotherapy       LMWH (enoxapatin domg Sc daily <sup>4</sup> )     condings     Physiotherapy       core by case basis     case by case basis     case by case basis	bbreviations: VTE: venous thromboembolism, UFH: unfractionated heparin, LMWH: low molecular weigh his document is based on current guidance by SIGN, ACCP and ICS. It is intended for use in the ca entrasacchandes, dagibatran) are not included due to problems of availability, but may be considered in in

# Figure 1: Reproduction of the proforma used for the purpose of the audit

#### Ethics

The need for individual informed consent was waived because this was a retrospective analysis of the routine care of patients, and there was no breach of privacy or anonymity.

#### Results

The characteristics of the two populations are outlined in table 1. In the first arm, compliance was found to be only 30.7% (95% confidence interval 12.4% - 60.0%). This had

improved to 63.3% in the second arm (95% confidence interval 45.5% - 78.2%). This difference was found to be statistically significant (one-tailed p value 0.02). Medical patients formed the largest single group in both arms, although there were more surgical and orthopaedic patients in the second part of our audit (table 1). The most common risk factors in our patients were immobility, active medical disease and obesity, and the most common active medical conditions listed were sepsis and pulmonary oedema.

#### Discussion

VTE prophylaxis is known to efficacious, safe and cost-effective.<sup>7-8</sup> Our audit suggests that a lot more needs to be done to improve compliance with guidelines. However, we also find the outcome encouraging, as it suggests that simple measures can greatly improve the level of care we provide. The main limitations of our audit are its small size and its retrospective approach. It was not powered to answer detailed questions about how we use VTE prophylaxis. During the same time period, an admission proforma was implemented at the main acute facility including a reminder to risk-assess patients for VTE, and may have contributed to our results. The larger number of orthopoaedic patients in the second part of our audit may also have contributed to the increase in compliance seen.

We can't overemphasise the importance of documentation – both of indications and contraindications for VTE, and of any patient preferences that influence clinical decisions. Simple measures, like hydration and early mobilisation, should be implemented generally for all patients.<sup>9</sup>

#### Conclusion

We should be guided by the experience of other centres, which have achieved excellent results using a variety of simple measures, regular re-audit and individual feedback.<sup>4</sup> We would particularly recommend making better use of our IT system which can be a powerful way to prompt staff to think of VTE.<sup>4</sup> We can also implement the same strategy in other areas of concern in patient management.

Table I : A comparison between	the two legs of the audit,
outlining patient characteristics	s and results.

<u>anning punem churacter</u>	isites una resuits.	
	1 <sup>st</sup> leg of audit	2 <sup>nd</sup> leg of audit
Number of patients included	38	40
Number of patients excluded	4	2
	<u> </u>	
Males (%)	17 (44.7%)	17 (42.5%)
Age ≤60 (%)	0 (0%)	1 (2.5%)
Age 61-70 (%)	2 (5.3%)	2 (5.0%)
Age 71-80 (%)	16 (42.1%)	17 (42.5%)
Age 81-90 (%)	18 (47.4%)	17 (42.5%)
Age >90 (%)	2 (5.3%)	3 (7.5%)
Reasons for primary admission <sup>*</sup>		
Medical	24 (63.2%)	17 (42.5%)
Surgical	2 (5.3%)	5 (12.5%)
Orthopaedic	4 (10.5%)	15 (37.5%)
Other (neurosurgery, rehabilitation, social issues)	8 (21.1%)	3 (7.5%)
DVT prophylaxis	7 (18.4%)	17 (42.5%)
Prophylaxis indicated at any time during admission <sup>#</sup>	13 (34.2%)	30 (75%)
Prophylaxis appropriately administered	4/13 (30.7%)	19/30 (63.3%)

\**Primary admission: for those patients transferred from other centres, refers to the reason for requiring acute care.* 

<sup>#</sup>*Risk factors cited: active medical conditions (e.g. heart failure, sepsis, acute coronary syndromes, NMS), active malignancy, decreased mobility (including stroke), obesity, previous VTE.* 

#### References

- Spencer FA, Lessard D, Emery C, Reed G, Golberg RJ. Venous thromboembolism in the outpatient setting. Arch internal Med. 2007 167;1471-1475.
- Edelsberg J, Hagiwara M, Taneja C, Oster G. Risk of venous thromboembolism among hospitalised medically ill patients. Am J Health Syst Pharm. 2006 Oct 15;63(20 Suppl 6):S16-22.
- 3. White R. The epidemiology of venous thromboembolism. Thrombosis research. 2007:119-391.
- Cohen AT, Agnelli G, Anderson Jr FA, Arcelus JI, Bergvist D, Brecht JG et al. Venous thromboembolism in Europe: the number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007 98: 756–64
- Geerts WH, Bergvist D, Pineo GF, Heit JA, Samama CM, Lasser MR et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008 133:3810-4530.
- 6. Fitzmaurice DA, Murray E. Thromboprophylaxis for adults in hospital. BMJ. 2007 334(7602):1017-8.
- Wein L, Wein S, Haas SJ, Shaw J, Krum H. Pharmacological venous thromboembolism prophylaxis in hospitalised medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med. 167(14):1476-86.
- Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thrombo-embolism in general surgery. Br J Surg. 88(7):913-30.
- 9. The Scottish Intercollegiate Guidelines Network; Prevention and management of venous thromboembolism. Viewed online at http://www.sign.ac.uk/pdf/qrg122.pdf.